Ambrx Biopharma is a biotechnology business based in the US. Ambrx Biopharma shares (AMAM) are listed on the NASDAQ and all prices are listed in US Dollars. Ambrx Biopharma employs 87 staff and has a trailing 12-month revenue of around $4.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $6.55 - $28.15 |
| 50-day moving average | $25.85 |
| 200-day moving average | $18.23 |
| Wall St. target price | $28.67 |
| PE ratio | 66.6667 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2024-03-22
| 1 week (2024-07-13) | nan% |
|---|---|
| 1 month (2024-06-20) | nan% |
| 3 months (2024-04-20) | nan% |
| 6 months (2024-01-24) | -100.00% |
| 1 year (2023-07-24) | -100.00% |
|---|---|
| 2 years (2022-07-22) | -100.00% |
| 3 years (2021-07-23) | 21.72 |
| 5 years (2019-07-20) | N/A |
Valuing Ambrx Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ambrx Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ambrx Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Ambrx Biopharma shares trade at around 67x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Ambrx Biopharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Revenue TTM | $4.1 million |
|---|---|
| Gross profit TTM | $7.4 million |
| Return on assets TTM | -18.62% |
| Return on equity TTM | -37.23% |
| Profit margin | 0% |
| Book value | $3.85 |
| Market Capitalization | $1.8 billion |
TTM: trailing 12 months
We're not expecting Ambrx Biopharma to pay a dividend over the next 12 months.
Ambrx Biopharma's shares were split on 11 October 2023.
Over the last 12 months, Ambrx Biopharma's shares have ranged in value from as little as $6.55 up to $28.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ambrx Biopharma's is -2.364. This would suggest that Ambrx Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ambrx Biopharma has bucked the trend.
To put Ambrx Biopharma's beta into context you can compare it against those of similar companies.
Ambrx Biopharma Inc. , a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.